- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer | 1 | GlobeNewswire (USA) | ||
| 21.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 13.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 13.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.02. | LIXTE Biotechnology announces $1.05M registered direct offering; shares fall | 3 | Seeking Alpha | ||
| 11.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 10.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement | 78 | GlobeNewswire (Europe) | PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 06.01. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 20.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 01.11.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 29.10.24 | Pre-market Movers: GlycoMimetics, BIO-key International, Lixte Biotechnology, Shuttle Pharmaceuticals, Profire Energy | 569 | AFX News | NORWALK (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green GlycoMimetics, Inc. (GLYC) is up over 163% at $0.4433.
BIO-key... ► Artikel lesen | |
| 23.10.24 | Lixte Biotechnology granted extension to meet Nasdaq listing rules | 3 | Investing.com | ||
| 23.10.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.10.24 | Lixte Biotechnology files to sell units, no amount given | 14 | Seeking Alpha | ||
| 23.10.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 05.09.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09.24 | Lixte Biotechnology Holdings, Inc.: LIXTE Receives U.S. Patent Issue Notification for Immune Oncology | 155 | GlobeNewswire (Europe) | Patent Covers Combining LIXTE's LB-100 with Various Innovative Cancer Immunotherapies PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW)... ► Artikel lesen | |
| 26.08.24 | Lixte Biotechnology Holdings, Inc.: First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company | 180 | GlobeNewswire (Europe) | PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,800 | -5,76 % | INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications | Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by... ► Artikel lesen | |
| OCUGEN | 0,581 | -6,89 % | Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease | MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | EQS-News: Mainz BioMed N.V.: Darmkrebsmonat März: Mainz Biomed setzt sich für einen Wechsel von Diagnose zur Prävention ein | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Darmkrebsmonat März: Mainz Biomed setzt sich für einen Wechsel von Diagnose zur Prävention ein
03.03.2025... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,490 | -12,00 % | Viking Therapeutics Unusual Options Activity | ||
| IMMUNITYBIO | 2,734 | -13,92 % | ImmunityBio GAAP EPS of -$0.09, revenue of $7.20M | ||
| MARINOMED BIOTECH | 13,150 | 0,00 % | EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes | EQS Veröffentlichung von Finanzberichten: Marinomed Biotech AG
/ Veröffentlichung von Finanzberichten
Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| ORAGENICS | 0,258 | 0,00 % | Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health | ||
| FIBROGEN | 0,361 | -7,63 % | FibroGen, Inc.: FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results | ||
| REVIVE THERAPEUTICS | 0,004 | +600,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures | TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| CAPRICOR | 13,840 | -6,74 % | Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.8% - Here's Why | ||
| BIOLINERX | 3,283 | -100,00 % | XFRA YP2: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOLINERX LTD. DL-... ► Artikel lesen | |
| RADIUS HEALTH | - | - | +850% CVR-Jackpot: Biotech-Tipp Radius Health beschert Anlegern Geldsegen | Der Optionsvoodoo-Chatraum von sharedealsPlus brummte letzte Woche vor Begeisterung, denn ein längst vergessener Trade sorgt für Jubelstürme und prall gefüllte Konten bei den Mitgliedern des Anlegerclubs... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,520 | 0,00 % | Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma | APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well... ► Artikel lesen | |
| SCHOLAR ROCK | 34,800 | -6,95 % | Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress | Submitted apitegromab U.S. Biologics License Application (BLA) for patients with spinal muscular atrophy in January 2025; U.S. launch anticipated in 4Q 2025
Remain on track to submit European Union... ► Artikel lesen |
LIXTE BIOTECHNOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,400 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.
